Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03706053 · ClinicalTrials.gov registry record · Phase 3
Midodrine Use in Septic Shock
A Phase 3 study, sponsored by University of Virginia.
- Terminated
- Registry status
- Phase 3
- Development phase
- 10
- Enrollment target
NCT03706053 is a Phase 3 study that was terminated before completion, run by University of Virginia. The registered enrollment target is 10 participants.
The verdict
NCT03706053, a Phase 3 study, was terminated before completion, sponsored by University of Virginia.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 10 participants
- Enrollment target
Study Summary
The investigators aim to perform a randomized, double-blind, placebo-controlled trial to investigate the efficacy of midodrine in decreasing time to IV vasopressor liberation in patients with septic shock.
Interventions
- OTHER placebo
- DRUG Midodrine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-11-05 |
| Est. Completion | 2022-02-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03706053
The ClinicalTrials.gov registry entry for NCT03706053 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT03706053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03706053 about?
NCT03706053 is a clinical study titled "Midodrine Use in Septic Shock". The investigators aim to perform a randomized, double-blind, placebo-controlled trial to investigate the efficacy of midodrine in decreasing time to IV vasopressor liberation in patients with septic shock.
What is the current status of trial NCT03706053?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 10 participants. The study started on 2018-11-05. Estimated completion is 2022-02-11.
What interventions are being tested in trial NCT03706053?
The interventions under investigation include: placebo (OTHER), Midodrine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03706053?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.